← All trials
NCT05548296
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2022
- Primary completion
- Jul 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Sep 21, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 333
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Acrivon TherapeuticsLead sponsor
- National Cancer Institute (NCI)Overall official - principal investigator
- GOG Foundation, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.